If the p38 inhibitors could be validated for a targeting combination of pEMT HNSCC, which is RCT and PD(L)-1-based immunotherapy (immune checkpoint blockade (ICB)) resistant [58], it could be the first valid therapeutic approach for this tumor. This evidence concerns the gene MAPK14 and neoplasm.